GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features

Blood

Volumn 123, Issue 19, 2014, Pages 3007-3015

  Wang, Tianjiao ^a   Feldman, Andrew L ^b   Wada, David A ^c   Lu, Ye ^a   Polk, Avery ^a   Briski, Robert ^a   Ristow, Kay ^b   Habermann, Thomas M ^b   Thomas, Dafydd ^a   Ziesmer, Steven C ^b   Wellik, Linda E ^b   Lanigan, Thomas M ^a   Witzig, Thomas E ^b   Pittelkow, Mark R ^b   Bailey, Nathanael G ^a   Hristov, Alexandra C ^a   Lim, Megan S ^a   Ansell, Stephen M ^b   Wilcox, Ryan A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD163 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; PREDNISONE; RUXOLITINIB; STAT1 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR GATA 3; VINCRISTINE; CYTOKINE; GATA3 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA INTERFERENCE; TH2 CELL; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOKINES; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; KAPLAN-MEIER ESTIMATE; LYMPHOMA, T-CELL, PERIPHERAL; MACROPHAGES; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA INTERFERENCE; T-LYMPHOCYTES; TH2 CELLS; TUMOR MICROENVIRONMENT;

EID: 84900402661     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-544809     Document Type: Article

References (49)

1. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417-1429.
2. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-2169. (Pubitemid 39507628)
3. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
4. Wilcox RA. Cancer-associated myeloproliferation: old association, new therapeutic target. Mayo Clin Proc. 2010;85(7):656-663.
5. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445-489.
6. Iqbal J, Weisenburger DD, Greiner TC, et al; International Peripheral T-Cell Lymphoma Project. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026-1036.
7. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
8. Weisenburger DD, Savage KJ, Harris NL, et al; International Peripheral T-cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402-3408.
9. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952-4963. (Pubitemid 46827794)
10. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621-663.
11. Wilcox RA, Wada DA, Ziesmer SC, et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood (ASH Annual Meeting Abstracts). 2009;114(14):2936-2944.
12. Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood. 2002;99(8):2929-2939. (Pubitemid 34525383)
13. Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114(10):2149-2158.
14. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-896.
15. Shoemaker J, Saraiva M, O'Garra A. GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. J Immunol. 2006;176(6):3470-3479. (Pubitemid 43363994)
16. Chang HD, Helbig C, Tykocinski L, et al. Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. Eur J Immunol. 2007;37(3):807-817. (Pubitemid 46916947)
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
18. Gallamini A, Stelitano C, Calvi R, et al Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474-2479. (Pubitemid 38392996)
19. Cox DR. Regression models and life tablets. J R Stat Soc.1972;34:187-202.
20. Ambarus CA, Krausz S, van Eijk M, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods. 2012;375(1-2):196-206.
21. Northcott PA, Shih DJ, Remke M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012;123(4):615-626.
22. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341(15):1112-1120. (Pubitemid 29466223)
23. Ravoet M, Sibille C, Gu C, et al. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood. 2009;114(14):2969-2983.
24. Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(11):928-948.
25. Rodriguez-Pinilla SM, Atienza L, Murillo C, et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol. 2008;32(12):1787- 1799.
26. Iqbal J, Wright G, Rosenwald A, et al. Gene expression signatures delineate biologic and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2012;120:679.
27. Bank I, Amariglio N, Reshef A, et al. The hypereosinophilic syndrome associated with CD4 1 CD3- helper type 2 (Th2) lymphocytes. Leuk Lymphoma. 2001;42(1-2):123-133. (Pubitemid 32700930)
28. Brugnoni D, Airó P, Rossi G, et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood. 1996;87(4):1416-1422. (Pubitemid 26056905)
29. Kluk MJ, Ashworth T, Wang H, et al. Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS ONE. 2013;8(6):e67306.
30. Sors A, Jean-Louis F, Pellet C, et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood. 2006;107(6):2354-2363. (Pubitemid 43345555)
31. Odqvist L, Sánchez-Beato M, Montes-Moreno S, et al. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells. Clin Cancer Res. 2013;19(9):2319-2330.
32. Darwiche N, Sinjab A, Abou-Lteif G, et al. Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas. Int J Cancer. 2011;129(4):993-1004.
33. Hegazy AN, Peine M, Helmstetter C, et al. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(1)T-bet(1) cell subset with combined Th2 and Th1 cell functions. Immunity. 2010;32(1):116-128.
34. Wang Y, Su MA, Wan YY. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity. 2011;35(3):337-348.
35. Wada DA, Wilcox RA, Weenig RH, Gibson LE. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis. J Cutan Pathol. 2010;37(5):535-541.
36. Kusam S, Toney LM, Sato H, Dent AL. Inhibition of Th2 differentiation and GATA-3 expression by BCL-6. J Immunol. 2003;170(5):2435-2441. (Pubitemid 36245631)
37. Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 2006;16(1):3-10. (Pubitemid 43129303)
38. Tai TS, Pai SY, Ho IC. GATA-3 regulates the homeostasis and activation of CD8+ T cells. J Immunol. 2013;190(1):428-437.
39. Wang Y, Misumi I, Gu AD, et al. GATA-3 controls the maintenance and proliferation of T cells downstream of TCR and cytokine signaling. Nat Immunol. 2013;14(7):714-722.
40. Hosoya T, Kuroha T, Moriguchi T, et al. GATA-3 is required for early T lineage progenitor development. J Exp Med. 2009;206(13):2987-3000.
41. Lemonnier F, Couronné L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466-1469.
42. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901-1903.
43. Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120(11):2280-2289.
44. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596-605.
45. Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915-919.
46. Gupta M, Han JJ, Stenson M, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012;119(12):2844-2853.
47. Sarris AH, Kliche KO, Pethambaram P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999;10(4):433-440. (Pubitemid 29236421)
48. Sugaya M, Miyagaki T, Ohmatsu H, et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci. 2012;68(1):45-51.
49. Niino D, Komohara Y, Murayama T, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60(4):278-283.